Updated Data From the LEAHRN Study in High-Risk Neuroblastoma
Experts review updated data from the LEAHRN study presented at the ASCO 2023 Annual Meeting highlighting the long-term toxicities experienced by high-risk neuroblastoma patients, particularly hearing loss, and the potential to modify treatments to reduce these effects.
EP: 1.An Overview of Neuroblastoma
EP: 2.Approaches to Diagnosing Neuroblastoma
EP: 3.Role of CURIE Scores in the Treatment and Management of Neuroblastoma
EP: 4.Current Treatment Paradigm for Newly Diagnosed Neuroblastoma
EP: 5.Differentiating Refractory and Relapsed Neuroblastoma
Now Viewing
EP: 6.Updated Data From the LEAHRN Study in High-Risk Neuroblastoma
EP: 7.Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)
EP: 8.Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials
EP: 9.Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R
EP: 10.Future Perspectives in the Treatment of Neuroblastoma
Related Videos
Related Content
